$Castle Biosciences (CSTL.US)$ New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma | CSTL Stock News
$Castle Biosciences (CSTL.US)$New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis 1 MINUTE AGO, 4:30 PM EDT VIA BUSINESSWIRE
Despite impressive revenue growth, the high P/S ratio and average growth expectations make the share price seem overvalued. Predicted future revenues may not support this positive sentiment, risking shareholders' investments and potential investors paying a premium.
Castle Biosciences' progress over the last year is impressive, and it is well-positioned to raise more cash for growth with minimal dilution or borrowing. Its cash burn situation is not risky due to revenue growth and cash burn reduction.
Investors are confident in Castle Biosciences' future growth despite its high P/S ratio. The strong future revenue growth justifies the high P/S ratio, making a significant share price drop unlikely.
Derek Maetzold, president and CEO of Castle Biosciences, sees the robust revenue and test volume growth as a testament to their successful execution of growth initiatives. He is optimistic about the sustainability of this growth and momentum into 2024.
$Castle Biosciences (CSTL.US)$Keeping a close eye to see what comes out of this? (. New Data Highlights Clinical Utility and Performance of Castle Biosciences' Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference Businesswire· 4 mins ago
Castle Biosciences股票讨论
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma | CSTL Stock News
加载中...
加载中...
Businesswire· 4 mins ago
暂无评论